Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | CHIT1 | Q13231 | 10/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHI3L1 | P36222 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551226 | 0.83 | PRMT6 (0.45) | KCNH2 | |
| SCHEMBL3548356 | 0.82 | HSD17B2 (0.47) | ALDH1A1L3MBTL1DRD2 | |
| SCHEMBL18609741 | 0.76 | CHI3L1 (0.45) | ALDH1A1LSSCHIT1CHIAKCNH2 | |
| SCHEMBL3548008 | 0.76 | ACHE (0.47) | LSS | |
| SCHEMBL3548022 | 0.75 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1 | |
| SCHEMBL3550805 | 0.75 | CXCR4 (0.43) | ALDH1A1KCNH2 | |
| SCHEMBL5146706 | 0.75 | CXCR4 (0.43) | ALDH1A1KCNH2 | |
| SCHEMBL3551208 | 0.73 | SLC6A3 (0.43) | ALDH1A1DRD2 | |
| SCHEMBL13344516 | 0.72 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL13369119 | 0.72 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714021-B2 | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080287523-A1 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287523-A1 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, APP | ALDH1A1 2813/4885LSS 462/4885CHIT1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.